{
  "study_id": "NCT06041152",
  "agent": "framework",
  "run": 4,
  "p_primary_hypothesis_supported": 0.12,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": -8, "high": 14, "metric": "Percent difference in SynVesT-1 volume of distribution, psilocybin vs placebo (positive = higher density after psilocybin)"},
  "moderator_prediction": "aMCI participants may show a slightly larger rise (lower baseline density leaves room, and deeper need for restructuring), but with 6 vs 4 participants no reliable moderator difference is expected; effectively none.",
  "claim_ids_used": ["PM-0028", "PM-0401", "PM-0369", "PM-0062", "PM-0058", "PM-0372", "PM-0086", "PM-0092"],
  "rationale": "The framework treats psilocybin as relaxing prior precision and opening the gate (PM-0028, PM-0401, PM-0369), and holds that belief balances are physically connection strength written in tissue that is slow but not impossible to change (PM-0058, PM-0062); one saturated session can book heavily (PM-0092). So a small positive shift in synaptic density is directionally consistent. But the framework expects smaller effects on biomarkers than on felt outcomes (PM-0086, PM-0372), and this is a 10-person, four-arm pilot measuring PET VT one week post-dose with high between-subject variance. Statistical significance against placebo is unlikely even if a true few-percent increase exists."
}